Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy)

• Type of Material: Article
• Authors: Paolo Ascierto, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”; Lisa H. Butterfield, Parker Institute for Cancer Immunotherapy; Katie Campbell, Parker Institute for Cancer Immunotherapy; Bruno Daniele, Ospedale del Mare; Michael Dougan, Harvard Medical School; Leisha A. Emens, University of Pittsburgh; Silvia Formenti, Weill Cornell Medicine; Filip Janku, The University of Texas MD Anderson Cancer Center; Samir N. Khleif, Georgetown University; Tomas Kirchhoff, New York University School of Medicine; Alessandro Morabito, IRCCS-Fondazione G. Pascale; Yana Najjar, University of Pittsburgh; Paul Nathan, Mount Vernon Cancer Centre; Kunle Odunsi, Roswell Park Comprehensive Cancer Center; Akash Patnaik, University of Chicago; Chrystal Paulos, Emory University; Bradley I. Reinfeld, Vanderbilt University; Heath D. Skinner, University of Pittsburgh; John Timmerman, University of California, Los Angeles; Igor Puzanov, Roswell Park Comprehensive Cancer Center
• Language: English
• Date: 2021-01-06
• Publisher: BMC
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2021.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s12967-020-02627-y
• Title of Journal or Parent Work: JOURNAL OF TRANSLATIONAL MEDICINE
• Volume: 19
• Issue: 1
• Start Page: 13
• End Page: 13
• Keywords: PATIENTS PTS; NECK-CANCER; MERKEL CELL-CARCINOMA; THERAPY; Vaccine; Research & Experimental Medicine; Life Sciences & Biomedicine; IPILIMUMAB; Combination therapy; Medicine, Research & Experimental; NIVOLUMAB; Tumor microenvironment; Science & Technology; STAGE-III MELANOMA; ANTITUMOR IMMUNITY; PD-1 BLOCKADE; PEMBROLIZUMAB; Checkpoint inhibitors; Immunotherapy; Biomarkers
• Research Categories: Health Sciences, Oncology; Health Sciences, Immunology

Abstract

Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with melanoma and extending to other tumours. The clinical success of immune checkpoint blockade has encouraged increasing development of other immunotherapies. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Evolving topics on cancer immunotherapy, including the state of the art of immunotherapy across various malignancies, were the focus of discussions at the Immunotherapy Bridge meeting (4–5 December, 2019, Naples, Italy), and are summarised in this report.